Sutro Biopharma (STRO) Stock Analysis

Sutro Biopharma (STRO) is a publicly traded company in the HEALTHCARE sector. It trades at $24.43, carries a market capitalization of $468.12M. This page summarizes the public market data, fundamentals, and frequently asked questions for STRO, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $24.43
• Market Cap: $468.12M
• EPS: $-16.35
• 52-Week High: $43.85
• 52-Week Low: $6.74

Market Sentiment

Sutro Biopharma currently has a Bullish sentiment score of 0.43.

About Sutro Biopharma

Sutro Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and manufacturing of innovative antibody-drug conjugates (ADCs) using its proprietary cell-free protein synthesis platform. Based in South San Francisco, California, Sutro is committed to advancing a robust pipeline of targeted therapies for cancer and other serious diseases. With its unique capabilities in protein engineering and biologics manufacturing, the company aims to address unme...

GNG Research Analysis

GNG Research scores Sutro Biopharma (STRO) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for STRO.

Frequently Asked Questions

Does STRO pay dividends?

Sutro Biopharma (STRO) does not currently pay a regular dividend.

What is STRO's market cap?

Sutro Biopharma (STRO) has a market capitalization of $468.12M with a current stock price of $24.43.